BSE filing, NSE: PRISMMEDI. Summary written from the filing by ALFA Finder's alert engine.
Prism Medico and Pharmacy Ltd: key numbers
- Share price
- ₹35.20
- Market cap
- ₹47.74 Cr
- Revenue (annual)
- ₹2.44 Cr
- Net profit (annual)
- ₹0.32 Cr
- P/E (TTM)
- -120.1×Sector 36.4×
- Promoter holding
- 29.98%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Prism Medico and Pharmacy Ltd
All →Prism Medico and Pharmacy Other Announcement
Prism Medico and Pharmacy Limited has informed that no interest, dividend, or principal is payable on non-convertible securities for the quarter ending December 31, 2026.
Prism Medico and Pharmacy Management Change
Prism Medico and Pharmacy Limited re-appointed Davender Singh as a Non-Executive Non-Independent Director. The company also updated its statutory and secretarial auditor appointments.
Prism Medico and Pharmacy Annual General Meeting
Prism Medico and Pharmacy held its 24th Annual General Meeting on September 19, 2026, to transact ordinary and special business, including various investment approvals.
Prism Medico and Pharmacy Annual Report
Prism Medico and Pharmacy Limited has filed its Annual Report for the financial year 2025-2026 in accordance with Regulation 34 of SEBI LODR Regulations.
Prism Medico and Pharmacy Annual General Meeting
Prism Medico and Pharmacy Limited has scheduled its 24th Annual General Meeting for September 19, 2026, through video conferencing to transact ordinary and special business.
Prism Medico and Pharmacy Board Meeting Outcome
Prism Medico and Pharmacy's board approved the Director's Report and the 24th AGM notice for September 19, 2026. It also recommended auditor appointments and preferential issue object variation.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.